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Abstract
Autism spectrum disorder (ASD) has captured the attention of scientists, clinicians and the lay public because of its uncertain
origins and striking and unexplained clinical heterogeneity. Here we review genetic, genomic, cellular, postmortem, animal
model, and cell model evidence that shows ASD begins in the womb. This evidence leads to a new theory that ASD is a
multistage, progressive disorder of brain development, spanning nearly all of prenatal life. ASD can begin as early as the 1st
and 2nd trimester with disruption of cell proliferation and differentiation. It continues with disruption of neural migration,
laminar disorganization, altered neuron maturation and neurite outgrowth, disruption of synaptogenesis and reduced neural
network functioning. Among the most commonly reported high-confidence ASD (hcASD) genes, 94% express during prenatal
life and affect these fetal processes in neocortex, amygdala, hippocampus, striatum and cerebellum. A majority of hcASD genes
are pleiotropic, and affect proliferation/differentiation and/or synapse development. Proliferation and subsequent fetal stages
can also be disrupted by maternal immune activation in the 1st trimester. Commonly implicated pathways, PI3K/AKT and
RAS/ERK, are also pleiotropic and affect multiple fetal processes from proliferation through synapse and neural functional
development. In different ASD individuals, variation in how and when these pleiotropic pathways are dysregulated, will lead to
different, even opposing effects, producing prenatal as well as later neural and clinical heterogeneity. Thus, the pathogenesis of
ASD is not set at one point in time and does not reside in one process, but rather is a cascade of prenatal pathogenic processes
in the vast majority of ASD toddlers. Despite this new knowledge and theory that ASD biology begins in the womb, current
research methods have not provided individualized information: What are the fetal processes and early-age molecular and
cellular differences that underlie ASD in each individual child? Without such individualized knowledge, rapid advances in
biological-based diagnostic, prognostic, and precision medicine treatments cannot occur. Missing, therefore, is what we
call ASD Living Biology. This is a conceptual and paradigm shift towards a focus on the abnormal prenatal processes
underlying ASD within each living individual. The concept emphasizes the specific need for foundational knowledge of a
living child’s development from abnormal prenatal beginnings to early clinical stages. The ASD Living Biology paradigm
seeks this knowledge by linking genetic and in vitro prenatal molecular, cellular and neural measurements with in vivo post-
natal molecular, neural and clinical presentation and progression in each ASD child. We review the first such study, which
confirms the multistage fetal nature of ASD and provides the first in vitro fetal-stage explanation for in vivo early brain
overgrowth. Within-child ASD Living Biology is a novel research concept we coin here that advocates the integration of
in vitro prenatal and in vivo early post-natal information to generate individualized and group-level explanations, clinically
useful prognoses, and precision medicine approaches that are truly beneficial for the individual infant and toddler with ASD.
Introduction
Autism spectrum disorder (ASD) has captured the attention
of scientists and clinicians, as well as the lay public, in part
because the clinical profile is so striking [1–3]. Affected
individuals may display reduced ability to perceive, and
engage in, every day social behaviors; they may display a
preoccupation with seemingly trivial aspects of the envir-
onment (e.g., a fascination with street signs or spinning
objects) and show challenges in expressing themselves
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verbally. Furthermore, there is considerable heterogeneity
in each of those domains. Some individuals with ASD
attempt to make friends and have good eye contact, while
others appear completely aloof; some have IQs that far
exceed normal average, while others are unable to talk [4].
Despite this interest and knowledge about ASD clinical
heterogeneity, the prenatal beginning stages of ASD in the
vast percentage of affected children are unstudied and
unknown. This is because most current approaches are
unable to examine the underlying abnormal fetal processes
in the child with ASD that lead to that child’s clinical and
neural outcomes. Thus, the prenatal and early post-natal
biological bases for the striking clinical heterogeneity
remain largely a mystery and controversial. Without this
understanding, “precision” medicine and treatments at the
individual child level do not exist in any meaningful way.
These major gaps are due to too little knowledge of what
we term ASD Living Biology: We use the term ASD Living
Biology to emphasize the critical need for the field to
acquire an integrated system of knowledge about an ASD
child’s development from abnormal prenatal beginnings to
early clinical stages, arguably the most important develop-
mental period in ASD. To gain that knowledge requires a
paradigm shift that acquires and integrates genetic and
in vitro prenatal molecular, cellular and neural measure-
ments with in vivo post-natal neural and clinical presenta-
tion and progression in each ASD child. Thus, ASD Living
Biology is a research concept we coin here that advocates
the integration of within-child in vitro prenatal and in vivo
post-natal information to generate individualized and group
level explanations, clinically useful prognoses, and effective
treatments for ASD. This ASD Living Biology approach
enables individualized explanations and clinically useful
prognosis and treatment. Such knowledge may lead to
“precision medicine” for ASD: individualized early-age
prognostic and treatment approaches. To specify such a
system, we must address fundamental questions: When does
autism begin? What are the initial molecular, neural, and
developmental perturbations and their subtypes? How is
neural development altered and what are the clinical
implications of these neural developmental changes? Across
the past decades, the answers to these questions were lar-
gely speculative and controversial.
An attempt to answer some of these questions stemmed
from our early brain overgrowth theory that posited that
ASD results from a prenatal disruption of neurogenesis that
generates an overabundance of cortical neurons and disrupts
circuit formation and function in large-scale frontal, tem-
poral and amygdala social and language networks [5–7]
(Fig. 1). This theory resulted from the discovery of enlarged
brain volumes in frontal and temporal cortex in many ASD
toddlers and young children as evidenced from magnetic
resonance imaging (MRI) [5, 8–14], increased cortical
surface area or thickness during early-age development [15–
18], increased volume of frontal axon tracts [19], acceler-
ated and atypical head circumference growth across early
life [20–22], and greater brain weight in ASD [23–25].
While it is also known that a subset of ASD have small
brain size, sometimes associated with extremely rare chro-
mosomal defects [26–29], a meta-analysis by Sacco et al.
[30] of 8,310 subjects from 44 MRI and 27 head cir-
cumference studies spanning toddlerhood to adulthood finds
significant brain and head circumference overgrowth in
ASD compared to controls across ages; the most pro-
nounced brain and head size increases occur at early ages.
Many now hypothesize that prenatal processes, such as
abnormal cell proliferation, might underlie early-age brain
growth defects in ASD [5–7, 24, 31–34], including both
ASD overgrowth and undergrowth. Mechanisms regulating
cerebral cell proliferation are well understood [35], and in
humans, this fetal stage occurs in the 1st and 2nd trimesters
(Fig. 2) [36–39]. Disruption of proliferation can have
downstream consequences for differentiation, cell fate,
migration, maturation, synapse development and circuit
patterns. Therefore, it is crucial to know whether disrupted
development in ASD begins as early as the proliferation
stage, and to know if this represents a small subset of ASD
or is more generally present.
Here we review recent postmortem, cell model, tran-
scriptomic, genetic, genomic systems and animal model
evidence that directly speaks to this specific theory of ASD
beginnings and to the general hypothesis that ASD involves
disruption of multiple fetal stages. We conclude that new
evidence supports a new theory that ASD is a progressive
prenatal disorder that precedes and produces post-natal
Fig. 1 Illustration of early brain overgrowth in ASD. Brain overgrowth
in the first years of life occurs in many ASD toddlers and is due to
prenatal cell cycle dysregulation that causes an overabundance of
cortical neurons. This is theorized to lead to disrupted neural network
development and function, and ASD symptoms [5–7, 24, 31–34].
Unbiased, blinded stereological analyses find that young ASD male
children have an average 67% more prefrontal neurons than con-
trols [24]. Since cortical neuron generation occurs only in prenatal life
in humans, this is direct evidence that ASD begins in the womb. As
discussed in this review and previously [56], abnormal early brain
undergrowth in toddlers with ASD may also be due to cell cycle
dysregulation. Adapted from Courchesne et al. [7]
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phenotypic heterogeneity. As such, we also conclude that a
paradigm shift toward an ASD Living Biology approach is
necessary to uncover the beginning stages of ASD in each
living child, understand how early neurobiological pro-
cesses lead to the striking clinical heterogeneity in ASD,
and develop “precision” treatments at the individual child
level.
ASD begins in the womb
ASD postmortem evidence
Strong evidence that ASD begins in the womb comes from
observations that young ASD male children have 67% more
prefrontal neurons than controls [24] (Fig. 1). Neuron
overabundance is not uniform in prefrontal cortex: Neuron
excess was 79% in dorsolateral and 29% in medial pre-
frontal cortex [24]. Moreover, the degree of neuron excess
across ASD cases was heterogeneous, ranging from 12 to
106%. In four ASD cases [24], neuron excess was >83% of
control average. One child had an excess of 106% and
mutation of PTEN, a high-confidence ASD gene. In another
study, cortex in young ASD cases had 36% more neurons
than controls [40] (Table S1). Young ASD males have
~53% more von Economo neurons in frontoinsular cortex
than controls [41]. Cell cycle, differentiation, and DNA
damage response genes and pathways are dysregulated in
prefrontal cortex at young ages in ASD, and immune gene
expression is upregulated [42]. Because proliferation of
cortical neurons is exponential between 10 and 20 weeks of
gestation [43, 44] and does not occur postnatally, patholo-
gical neuron excess cannot be caused by post-natal events
and instead indicates neural disorder in ASD has a prenatal
origin, likely by the first and/or second trimester.
In ASD, neural migration and cortical laminar organi-
zation, stages that occur in second and third trimesters, are
also abnormal (Fig. 2) [34, 45–48]. Patches of focal laminar
disorganization and nearby clusters of mis-migrated neu-
rons were found in prefrontal and temporal cortices in 10 of
11 young ASD cases [34]. In these cases, there was
heterogeneity in cortical cell types and layers that were most
disrupted. While all layers were affected, patches tended to
be pronounced in layers 2, 3 and 4. Patches of cortical
dysplasia could be due to somatic mutations [49]. Somatic
mutations (e.g., in the PI3K/AKT/mTOR pathway) also
occur in hemi-megaencephaly and intractable epilepsy and
may be an important prenatal source of phenotypic het-
erogeneity and risk in ASD and other neurodevelopment
disorders [50].
Neuropathology examination of 4-year-old to 60-year-
old ASD brains shows evidence of multiregional dysregu-
lation of neurogenesis and neuronal migration in several
cases, including subcortical, periventricular, hippocampal
and cerebellar heterotopias reflecting abnormal neuronal
migration and multifocal cerebral dysplasias [45]. Complete
removal of the subplate, which normally occurs in the third
trimester, may also be disrupted in ASD [47, 51]. Reduced
growth of neuronal cell size and dendritic arbors in ASD
postmortem cases have long been reported [25, 52] and are
now recognized as an important neuropathological attribute
of ASD cortex [46]; neuron size reduction varies from −4%
in occipital to −18% in prefrontal cortex [24, 40, 53].
ASD patient-derived iPS cells
To test whether disruptions in proliferation and prenatal
neural developmental stages are related to early brain
overgrowth in vitro in ASD, Marchetto et al [54] derived
iPS cells from fibroblasts from living ASD toddlers with
early brain overgrowth and from control toddlers. iPS cells
were differentiated to neural progenitor cells and then
neurons. ASD neural progenitor cells display excess pro-
liferation compared to normal controls (Fig. 3a–d), and that
excess proliferation was correlated with the degree of each
child’s MRI-based brain overgrowth (Fig. 3e). This sug-
gests dysregulated proliferation contributes to early brain
overgrowth in ASD toddlers. Excess proliferation of iPS
cells and radial glia cell stage and cell cycle acceleration
were also found by Mariani et al [55] in iPSCs derived
from a small sample of ASD patients with brain enlarge-
ment. In Marchetto et al. [54], ASD neural progenitors
Fig. 2 Developmental timeline
relevant to ASD. Schematic of
prominent processes occurring
during different periods of
human fetal and post-natal brain
development. Adapted from
Lombardo et al. [127]
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doubled in number twice as fast compared to controls due to
a shorter cell cycle G1/S phase. Further, reduced β-catenin
and BRN2 transcriptional activity was related to this pro-
liferation abnormality. There was also earlier but less
complete cell differentiation.
Multiple subsequent fetal age processes were also
abnormal in every ASD case in Marchetto et al [54]. ASD
patient-derived neurons additionally displayed fewer exci-
tatory synapses, and downregulation of multiple neuro-
transmitter and synapse markers including GABA receptor
markers (Fig. 3f, g). With increasing age from 30 to 50 days
of development, ASD-derived neural networks showed less
spontaneous excitatory activity and poorly synchronized
activity. By 50 days, synchronized neural bursts of activity
were 6 times lower in ASD than controls (Fig. 3h, i). The
ASD subject with the greatest cell proliferation and brain
size has a PTEN mutation and is not intellectually disabled
but has severe social communication symptoms. Mariani
et al. also reported multiple disrupted fetal stages in their
ASD iPSC study [55], and interestingly these included
excessive synaptogenesis. Thus, ASD patient-derived iPSC
studies find evidence of multiple fetal stage defects with
commonality in excess proliferation and cell cycle accel-
eration defects, but heterogeneity in synaptogenesis effects.
This points to fetal stage subtypes in ASD.
These ASD Living Biology experiments suggest that
neural developmental disorder in ASD spans prenatal and
early post-natal life, beginning with dysregulation of cell
cycle G1/S and excess cell proliferation and ending
with disrupted synaptogenesis and dysfunctional nascent
Fig. 3 Excess cell proliferation, abnormal synaptic development and reduced neural activity are associated with iPS cells of ASD toddlers with enlarged
brains. a ASD iPS cells proliferate more rapidly than control. The iPS cells from ASD and control were differentiated to NPCs. From passages 2 to 6, cells
were plated at the same density and population doubling time at each passage was calculated. Results of all lines (2 clones per line) are presented as mean ± s.e.
m. (*repeated measurements P= 0.02, post hoc P< 0.04). b ASD cell cycle has abnormally short G1 phase. Adherent monolayer NPCs from control and
ASD iPS cells were dissociated, counted for calculation of population doubling time and prepared for cell cycle analysis. Results are presented as the time
spent in each cell cycle stage (n⩾ 4, mean ± s.e.m., analysis of variance (ANOVA) P< 0.04, post hoc P< 0.04 for comparing the time spent in G1 phase in
the ASD NPCs with those of the control NPCs, respectively). c Control and ASD NPCs were immunostained with 4′,6-diamidino-2- phenylindole (DAPI;
blue), anti-pHH3 (green) and anti-ki67 (red) (scale bar: 200 μm). Representative images of the staining are shown. dQuantification of the percentage of Ki67+
− and Ki67+ pHH3+−labeled cells are presented as mean ± s.e.m. (n⩾ 5; *P< 0.03 for comparing the results of the ASD with those of the control NPCs). e
Greater proliferation rates in ASD were correlated with greater early brain overgrowth. Pairwise correlation between individual brain size (volume) and
respective NPC cell line proliferation rates (% of Ki67-positive cells). ASD displays reduced and deviant synaptic development as shown in panels f and g. f
Representative images of synaptic processes from cells after neuronal differentiation (Map2, blue). The iPSC-derived neurons express markers for excitatory
neurons, such as postsynaptic density protein 95 (PSD95, red) and vesicular glutamate transporter 1 (VGlut1, green) (scale bar: 5 μm). g Bar graphs show
synaptic puncta size in ASD vs control neurons (P< 0.05 for comparing the results of the ASD with those of the control neurons), and GABA-positive
neurons in all ASD-derived neurons compared with all controls (*P< 0.001). h ASD neural activity is sharply reduced. Representative image of number of
spikes recorded over 10min at 50 days of culture maturation (n= 3 wells per cell type). i ASD neural activity is sharply reduced. Top, total number of spikes
from data obtained from controls (n= 6) and ASD (n= 10) clonal lines differentiating over 30 days and controls (n= 4) and ASD (n= 9) clonal lines at
50 days after differentiation over 10min of recording. Results are presented as mean ± s.e.m. (*P= 0.0046 for comparing the results of the ASD with control
networks). Bottom, number of network bursts from wells that were able to generate bursts (10 spikes over 100ms). Results are presented as mean ± s.e.m. (*P
< 0.0001 for comparing the results of the ASD with control networks). Images adapted from Marchetto et al. [54]
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neural circuit activity. Heterogeneity already exists at these
early stages. Mechanisms that dysregulate proliferation may
dysregulate neural differentiation, cell fate determination
and maturation. The conclusion that dysregulation of pre-
natal cell cycle G1/S underlies excess proliferation and
early brain overgrowth in these toddlers with ASD is
strongly supported by these ASD patient-derived iPS cell
data.
Transcriptomic evidence in living ASD toddlers
points to prenatal periods
Transcriptomics of leukocytes from ASD toddlers reveal
further insights into ASD Living Biology. In analyses of
gene expression and MRI measures of brain size at young
ages, ASD toddlers with the most abnormal expression of
cell cycle hub genes had the most brain overgrowth, while
those with milder cell cycle disruption had smaller than
normal brain size [56]. Functional genomic analyses iden-
tified 23 candidate genes for brain maldevelopment linked
to 32 upstream high-confidence ASD genes [56]. Dysre-
gulation of cell cycle G1/S was identified as contributing,
suggesting shortened G1/S in bigger ASD brains, consistent
with Marchetto et al [54]. CHD8 is one of the most com-
monly found high-confidence ASD mutations [57, 58, 62,
66], and the analyses of a CHD8 subnetwork and altered
CHD8-regulated transcript levels further confirmed the
central role of genes regulating neurogenesis and cell
adhesion processes in ASD brain maldevelopment [56].
Thus, in living ASD infants and toddlers, patient-derived
iPS cell experiments and leukocyte transcriptomics point to
dysregulation of cell cycle G1/S.
High-confidence ASD genes and prenatal
development
In a small percentage of children with ASD, rare de novo
gene mutations are risk factors [58–65]. Genetic informa-
tion accumulated via these and many other studies enable
the search for likely ASD genes and gene networks.
Unraveling how these mutations affect brain development is
crucial to advance understanding of how genetic, non-
genetic and gene/environment interactions cause ASD
and influence neural development, clinical progression, and
treatment. However, new evidence shows many proposed
gene associations may be “noise” [66]. Of the hundreds of
potential associations, 38 genes are classified as recurrent
and potentially penetrant in ASD [66]. Of these 38 genes,
31 also overlap with the 65 SFARI Level 1(S) and 2(S) ASD
genes; taken together, these 72 genes are high-confidence
ASD (hcASD) genes.
These 72 hcASD genes, many of which regulate gene
expression, are the most penetrant genes implicated in ASD
thus far. It is crucial to understand how they contribute to
brain growth and function because they may point to pro-
cesses central to ASD development. Previous analyses of
ASD risk genes were performed when knowledge of hcASD
genes was more limited [67, 68], and some of those ana-
lyses gave similar weight to both low and high-confidence
genes. Thus, the developmental roles of these 72 hcASD
genes may have been obscured by inclusion of low con-
fidence genes; so further study of these hcASD genes is
needed.
Here we use these 72 hcASD genes to address three
central questions: When during development do hcASD
genes play developmental roles? Where in the brain do they
do so? What functional roles may they play? First, we
addressed the “when and where” roles of these hcASD
genes by leveraging the most recent BrainSpan RNA-Seq
dataset (http://www.brainspan.org/). Of the 72 genes, 3 are
not detected (RPKM > 0.5) in >10% of BrainSpan samples
between prenatal and up to 8 years old post-natal. There-
fore, here we focus on the 69 hcASD genes that do have
reliable expression levels.
Of these 69 genes, 65 (94%) are expressed (RPKM > 1)
in prenatal brain development. Importantly, 47 genes (68%;
green cluster in Fig. 4) have peak expression during much
of prenatal development, and then are downregulated fol-
lowing birth. Furthermore, they display peak expression in
brain regions that are abnormal in ASD, including major
cerebral cortical areas, hippocampus, striatum (Fig. 4), and
cerebellum. From the perspective of biological roles, these
hcASD genes are largely associated with proliferation and
differentiation. Many are also involved in neural migration,
neurite outgrowth, and early synaptogenesis (Fig. 4). The
remaining 22 (32%) of the hcASD genes start to increase in
expression levels during the 3rd trimester and the first sev-
eral years of post-natal life (Fig. 4; purple cluster). They
also express in multiple, widespread brain systems known
to be abnormal in ASD (Fig. 4).
Second, we addressed “what” developmental role all 72
hcASD genes play, and found studies that support invol-
vement of 58 out of 72 hcASD genes in at least one of the
four main brain development processes including pro-
liferation/neurogenesis, cell fate/migration, neurite out-
growth, and spine development/synaptogenesis/synapse
function (Table S2). Of these 58 hcASD genes, 33 (57%)
hcASD genes are involved in cell proliferation and/or neu-
rogenesis, while 34 (59%) are involved in spine develop-
ment, synaptogenesis, and/or synapse function (Fig. 5).
Importantly, our analysis underscores a crucial feature
shared by the majority of hcASD genes, which is functional
pleiotropy. Indeed, 36 out of 58 (62%) hcASD genes are
involved in multiple major developmental processes
(Fig. 5). While hcASD genes have been historically
described to play primary roles in synaptic development and
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function, it is becoming increasingly clear that this view
may represent only a partial understanding of how they
contribute to ASD pathophysiology, which begins earlier
during development. For example, MECP2 is known as
critical player for synapse development and function of
GABA-releasing neurons [69, 70]; however, its involve-
ment spans early stages of cortical cell proliferation (likely
enhanced proliferation in ASD) [71, 72, 73], neurogenesis
and neural migration [73, 74], and neurite outgrowth [75].
SHANK3, a prototypical ASD gene coding for a post-
synaptic scaffolding protein in excitatory synapses [76],
also contributes to neurogenesis and morphogenesis during
early brain development [77].
While our analysis highlights the roles of several hcASD
genes, it is expected that further work will continue to
propose and validate new genes. For example, a recent
machine learning approach leveraged previously implicated
genes to generate predictions of plausible new autism risk
genes [78]. They further demonstrated that these genes
converge on fetal and early infancy stages, and were
involved in processes including cell cycle, embryogenesis,
morphogenesis, axonogenesis and synaptogenesis [78].
Furthermore, these genes also affect multiple brain struc-
tures, and are implicated in G1/S, RAS/ERK-PI3K/AKT
signaling, and chromatin remodeling.
In summary, our analyses of hcASD genes (Fig. 4) and
emerging work on newly predicted ASD risk genes high-
light two major human neural development epochs. First,
these genes are highly active during early fetal stages of cell
proliferation, differentiation, migration and early organiza-
tion. Second, they impact late fetal generation of synapses
and functional assemblies that continue on through birth
and impact the early experience and learning years. Thus,
hcASD gene evidence dovetails neatly with ASD patient-
derived iPS cell and leukocyte transcriptomic evidence in
ASD toddlers, and ASD postmortem evidence reviewed
above.
Pleiotropic common pathways implicated in
ASD
Among the hcASD genes, at least 48 (67%) genes are
involved in gene regulation including chromatin structure,
transcription, translation, and post-translation stages. This
suggests that perturbations of gene regulation contribute to
ASD. Consistently, studies on hcASD genes and iPSC-
derived ASD neurons highlight signaling pathways that are
commonly disrupted, such as PI3K/AKT [79, 80], RAS/
ERK [79, 80, 82, 83], WNT and β-catenin [57, 83, 84].
These signaling pathways are highly interconnected with
crosstalk and convergence points (Fig. 6) that can vary
based on the cell context and strength of input signal
[85–87]. In neural development, these pathways are crucial
in different fetal and early post-natal stages (Fig. 6;
Table 1), suggesting that the pleiotropic concept can be
extended from genes to molecular pathways.
Dysregulation of proliferation and neurogenesis
Multiple ASD risk factors, including PTEN, MECP2,
CHD8, ARID1B, ERBIN, and the 16p11.2 locus, link ASD
Fig. 4 The majority of hcASD genes show peak expression during prenatal life in different brain regions. Heatmaps demonstrate the developmental
expression patterns (x-axis) of 69 hcASD genes (y-axis) in different brain regions in prenatal and post-natal development. In the large neocortex
heatmap, hierarchical clustering of neocortex developmental transcriptome reveals two main clusters of genes, one cluster displayed in green and
the other in purple (see y-axis of heatmap). Proliferation and neurogenesis hcASD genes make the largest contribution to the green cluster, and
synapse development and function hcASD genes make the largest contribution to the purple cluster; see the two pie charts on the far left. This
clustering pattern is present across different neocortex regions and, to a lesser degree, in hippocampus and striatum (see green and purple hcASD
gene cluster patterns on y-axis of the other six heatmaps). FC: frontal cortex, Hippo: Hippocampus, OC: occipital cortex, PC: parietal cortex,
Str: striatum, TC: temporal cortex.
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to the disruption of neuron production through the PI3K/
AKT, RAS/ERK, WNT and β-catenin pathways (Table 1).
In precursor and radial glial cells (RGCs), upregulation of
PI3K/AKT, WNT and β-catenin or downregulation of RAS/
ERK leads to elevated proliferation [86, 88, 89]. The role of
these pathways reverses in intermediate progenitor cells
(IPCs). Activity of β-catenin (downstream of PI3K/AKT
and WNT, Fig. 6) enhances premature differentiation of
neurons [88], while activity of RAS/ERK reduces neuro-
genesis of IPCs and increases astrogenesis [90]. During
human brain development, precursors differentiate into
neurons first and glial cells later [91]. Therefore, dysregu-
lation of proliferating precursor cells will perturb the
number of generated neurons as well as the balance between
neurogenesis and gliogenesis in the developing brain. One
of the primary mechanisms that regulate neuroprogenitor
divisions is the rate of cell cycle progression, particularly
G1/S transition time [92, 93]. Studies on CHD8 and iPS-
derived ASD neurons indicate the dysregulation of pro-
liferation and macrocephaly in ASD could be linked to the
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Fig. 5 Distribution of 58 hcASD genes in four main categories of neural development. Functional annotation could be found for 58 hcASD genes
based on a manual literature search. Most highly penetrant ASD genes are pleiotropic, being involved in multiple stages of brain development. The
small pie-charts in each region indicate the percentage of genes in green and purple clusters from Fig. 4. The gray color in pie-charts represents
percentage of genes with no strong expression level in fetal and early post-natal periods. A gene is marked by an asterisk (*) if its function was
inferred from evidence in adult neural stem cells, embryonic or hematopoietic stem cells, central nervous system other than brain, or, for one gene,
cancer (see Table S2 for details and references).
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WNT or β-catenin
Fig. 6 The RAS/ERK, PI3K/AKT, WNT and β-catenin signaling pathways are involved in different stages of brain development and are
commonly disrupted in ASD. The schematic on the left indicates that these signaling pathways are highly interconnected and modulate different
aspects of brain development. For this illustration, the pathways are simplified and some intermediate genes are not shown. In the table on the right,
a plus sign (+) for each pathway indicates that its dysregulation has been reported in the corresponding fetal developmental stages based on
studies on either hcASD genes, ASD-derived neurons, or both (double plus signs).
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Table 1 Examples of hcASD genes that converge on and disrupt RAS/ERK, PI3K/AKT, WNT and β-catenin signaling pathways
Gene name Pathway involved Examples of effects on pathways
FMR1b,c,d PI3K/AKT Fmr1 knock-out mice have elevated activation of PI3K/AKT signaling pathway, affecting
synaptic plasticity with behavioral and cognitive defects. Downregulation of PI3K in prefrontal
cortex of Fmr1 null mice ameliorates aberrations in protein synthesis, dendritic spine density and
cortical network activity.
FOXG1b PI3K/AKT The PI3K/AKT signaling pathway affects cell fate determination and neural migration by
regulating FOXG1.
NLGN3a,c,d PI3K/AKT NLGN3 secretion by active neurons enhances proliferation of glial cells by activation of PI3K/
AKT pathway. Also affects synaptic development.
PTENa,b,c,d PI3K/AKT Pten+/- mice show high activity in PI3K/AKT and β-catenin signaling resulting in enhanced
proliferation of radial glial cells and cortical overgrowth; neuronal hypertrophy, hypertrophic and
ectopic dendrites and axonal tracts; increased synapses; and hyperconnectivity of prefrontal
cortex with amygdala. Pten also involves in neural migration.
RELNb,c,d PI3K/AKT PI3K/AKT signaling pathway affects cell fate determination and neural migration by regulating
RELN. While RELN promotes neuronal maturation, synaptic formation and plasticity, it appears
to be more important for dendrite and spine development via PI3K/AKT/mTOR pathway.
SHANK3a,c,d PI3K/AKT Mice with Shank3 mutations show deficits in synaptic function, hippocampal LTP and motor
performance that can be improved with IGF1 treatment. Also affects neurogenesis.
MECP2a,b,c,d PI3K/AKT and
RAS/ERK
iPS-derived RG cells from Rett syndrome patients with MECP2 mutation exhibit excess
proliferation through activation of PI3K/AKT and downregulation of RAS/ERK pathways.
Neurons with MECP2 knock-down fail to attain a unipolar/bipolar shape, display abnormal
migration and reduced cortical thickness. Neuron models of MECP2 mutations lead to
abnormalities in soma size, dendritic arborizations, spine density, and neuronal firing that may be
partially rescued by inhibiting Pten gene or IGF1 treatment.
ARID1Ba,c,d PI3K/AKT, WNT
and β-catenin
ARID1B suppression delays cell cycle re-entry. Mice with Arid1b knock-down show suppressed
IGF1, a mediator of PI3K/AKT and β-catenin pathways, resulting in decreased dendritic
arborization and accumulation of aberrant dendritic spines and altered synaptic transmission.
16p11.2a,d RAS/ERK 16p11.2 is one of most recurrent CNVs in ASD and encompasses multiple genes including
ERK1. Its deletion dysregulates RAS/ERK with effect on proliferation and neurogenesis of
murine neural progenitor cells. 16p11.2 mutation mouse models show reduced RAS/ERK
activity, reduced protein synthesis and cognitive impairments.
ERBINa,d RAS/ERK ERBIN has an inhibitory effect on RAS/ERK signaling pathway. Upregulation or downregulation
of Erbin leads to enhanced or decreased differentiation of PC12 neurons, respectively.
KAT2Ba,b,c,d RAS/ERK Null mutations lead to dysregulation of RAS/ERK and disruption of the pyramidal cell layer
organization.
NF1d RAS/ERK Mice with Nf1 null mutations show dysregulated RAS/ERK pathway and deficits in spine
morphology, glutamate and GABA release, hippocampal LTP and learning abilities.
SYNGAP1c,d RAS/ERK SYNGAP1 acts as RAS inhibitor, and heterozygote mutations in mice show premature neurons,
elevated excitatory synaptic transmission, reduced axonal branching and synaptic boutons in
inhibitory neurons, and deficits in behavior and cognition. Rescuing Syngap1 in adulthood did
not benefit the mice, underscoring its role in prenatal and early post-natal brain development.
CHD8a,d WNT and β-catenin CHD8 knock-down disrupts G1/S phase, dysregulates proliferation in neural progenitor and stem
cells and causes brain overgrowth. Chd8 mutations in mice result in abnormalities in striatal
circuitry and synaptic physiology
CTNND2a,c,d WNT and β-catenin Affects proliferation of glioma cells and involved in glioblastoma. Regulates spine morphology;
mutations decrease spines and excitatory synapses in hippocampal neurons in rodents. Ctnnd2
mutation in mouse models have impaired spatial learning and fear conditioning.
See Supplementary Table S3 for references to individual studies
Functional Roles in Development (also see Fig. 5)
a Neural/Glial Proliferation and Neurogenesis
b Neuronal Fate Determination and Migration
c Neurite Outgrowth
d Synaptogenesis and Synapse Function
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disruption of these signaling pathways and shortened G1/S
transition[54, 55, 57, 94, 183, 192, 193]. Importantly, the
induced proliferation by the signaling pathways can result
in either a thicker or thinner cortex in mice models
depending on the strength of the dysregulation. While
downregulation of RAS/ERK can lead to a thicker cortex
from increased proliferation and an increased neuronal
count [86], loss of Erk2 can induce such strong G1/S dys-
regulation that mice cells miss the time window of neuro-
genesis (E14.5–E16.5), resulting in fewer neurons,
precocious astrogenesis, and potentially microcephaly [95].
The other key factor that controls neuron numbers is the
balance between cell cycle re-entry (proliferative divisions)
and exit (neurogenesis). During brain development, RGCs
can divide symmetrically or asymmetrically. While sym-
metric divisions result in two daughter RGCs, asymmetric
divisions produce a RGC and one another cell [96]. The
newly generated cell can differentiate into a neuron, or
become an IPC [97]. IPCs can undergo 1–3 proliferation
cycles before differentiation to neurons [97, 98]. Cortical
surface area and thickness are controlled by the mechanisms
involved in RGC and IPC proliferation and differentiation
decisions [99, 100]. Interestingly, G1/S transition rates
might be associated with these cell decisions as symmetric
divisions can have shorter G1/S transition times than
asymmetric divisions [93, 101]. Evidence suggests that
PI3K/AKT, RAS/ERK, WNT and β-catenin pathways are
major players of these cell decisions as well. RGCs in a
mouse model of Gsk3 knockout, a major convergence point
of the signaling pathways (Fig. 6), show more highly active
β-catenin and Notch pathways [102]. As a result, RGCs
were locked in proliferative state with attenuated neuro-
genesis [102]. This resulted in expanded RGC pools, fewer
IPCs, reduced cortical thickness and increased ventricular
apical surface length [102]. Hence, it is tempting to spec-
ulate that perturbation of these four pathways in ASD could
involve dysregulation of balance between proliferation and
neurogenesis as well as neurogenesis and gliogenesis.
Disruption of cell fate and migration
Studies on MECP2, KAT2B, REELIN and FOXG1
hcASD genes suggest that they are associated with changes
to the cell fate determination and neural migration processes
in ASD through PI3K/AKT, RAS/ERK, WNT and
β-catenin pathways (Table 1). Upregulation of WNT and
β-catenin signaling, for example, prevents the multipolar to
bipolar transition of pyramidal precursors [103]. Thus,
neurons fail to migrate to the cortical plate and accumulate
within the intermediate zone [88, 104]. Somatic mutations
can also lead to dysregulation of these signaling pathways
during brain development. Somatic activating mutations in
the PI3K/AKT pathway are associated with
hemimegalencephaly and focal cortical dysplasia syn-
dromes that are marked by cortical dyslamination, dys-
morphic neurons and loss of radial neuronal orientation [50,
105, 106]. Thus, in addition to modulating neuron devel-
opment, the perturbed pathways in ASD also alter cell fate
determination and neural migration.
Dysregulation of neurite outgrowth and neuronal
function
The hcASD genes SHANK3, FMR1, CTNND2, CHD8,
SYNGAP1, MECP2, PTEN, ARID1B and NF1 are asso-
ciated with dysregulation of neurite outgrowth and neuronal
function through the PI3K/AKT, RAS/ERK, WNT and β-
catenin signaling pathways (Table 1). These pathways
control soma size, dendritic arborization, axon generation,
spine development and synapse function [184–188].
Activity of receptor tyrosine kinases, metabotropic glutamic
receptors and NMDA receptors lead to the activation of
PI3K/AKT and RAS/ERK signaling pathways [185, 189],
and thereby influence synaptic plasticity by mediating
expression and trafficking of AMPA receptors in excitatory
synapses and controlling long-term depression (LTD) and
long-term potentiation (LTP) responses [188–190]. PI3K/
AKT and RAS/ERK signaling pathways also control pro-
cesses associated with neural excitotoxicity and cell survi-
val [191]. Interestingly, it seems that hcASD genes do not
impact these pathways in the same way. For example, while
mutations in Fmr1 and Pten lead to the over-activity of
PI3K/AKT pathway with increased synaptogenesis and
hyperconnectivity of the neurons [107–109], mutations in
Mecp2 and Shank3 are reported to suppress the pathway,
leading to delayed and sparse spine development and
reduced synaptic amplitude [110, 111]. Interestingly, in
cases of Mecp2 and Shank3, neurons could be partially
rescued by activating PI3K/AKT pathway through Pten
inhibition or IGF1 treatment, while downregulation of the
pathway in Fmr1 null mice ameliorated aberrations in
protein synthesis, dendritic spine density and cortical net-
work connectivity [108, 109].
Finally, by prenatal injection of a small molecule that
stabilizes axin, a component of the WNT and β-catenin
signaling pathway, cell cycle proliferation is prolonged and
causes an excess of layer 2 and 3 neurons and early brain
overgrowth, abnormal synaptogenesis and increased exci-
tatory neural activity [112]. This was accompanied by ASD-
like abnormal social, vocalization, and ritualistic behaviors.
These results strengthen the causal link between cell cycle
disruption and ASD and also suggest that non-genetic
etiologies may underlie deviant neurodevelopmental
trajectories.
Thus, RAS/ERK, PI3K/AKT, WNT and β-catenin are
highly integrated and pleiotropic, exhibiting different and
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successive roles throughout prenatal and early post-natal
life (Fig. 6). Across ASD individuals, variation in how and
when these pleiotropic pathways are dysregulated will cause
early heterogeneity of pathophysiology and potentially later
neural and clinical heterogeneous outcomes.
The prenatal maternal immune activation
model of ASD
Non-genetic etiologies may account for 30–41% of the risk
for ASD [113], and such factors may act independently or
in combination with genetic factors [113]. A well-
established non-genetic model system for studying ASD
pathophysiology is the prenatal maternal immune activation
(MIA) model [114–116]. The link between MIA and
enhanced risk for ASD is bolstered by large-scale popula-
tion-based studies showing small but significantly increased
risk due to maternal prenatal infections [117–122]. MIA
models have ASD-like social, vocalization, ritualistic,
exploration and other behavioral deficits [123–125]. Current
MIA ASD models expose developing rodent pups to bac-
terial or viral mimetics [126] to elicit strong immune
responses. This is timed to roughly mimic infection between
8 to 12 weeks during the 1st trimester in humans, when
neural progenitor cells are proliferating to expand cortical
surface area and promote cortical layering [37, 39].
MIA strongly upregulates cell cycle gene expression
and cell proliferation, and may cause brain overgrowth
[127–129]. Similar to some ASD cases, MIA induces
overproduction of neurons [129], and increases cortical
thickness [129, 130] and brain size [130] as seen in many
toddlers with ASD [5, 8, 10, 13, 14, 18]. Gene expression
alterations also involve neuronal migration processes [128]
that could underlie observed cortical layering defects,
characterized by a 24% increase in neuron numbers in
cortical layers II/III [131]. MIA can also induce more
complex cortical phenotypes such as focal cortical dysplasia
[81, 132], similar to those found in ASD [34] (Fig. 7). Also,
cytoarchitecture heterogeneity is seen that is characteristic
of ASD cases [34, 132]. When focal cortical dysplasia is
present, ASD-like behaviors occur; but when its develop-
ment is prevented, ASD-like behaviors do not occur [81].
In addition to causing dysregulation of proliferation,
abnormal neuronal migration and dysplasia, increased brain
size and ASD-like behavior, MIA animal models also lead
Fig. 7 In a single litter, a single prenatal poly(I:C) injection may cause different cortical layering defects across pups that resemble some types of
focal cortical dysplasias seen in different individuals with ASD. a Expression of multiple layer-specific markers (II–IV and V, VI) in mouse cortex
from Choi and colleagues [81, 132]. Typical mouse cortex layer development is shown in upper left corner (PBS), while heterogeneous types of
focal cortical dysplasia are caused by prenatal maternal immune activation (MIA) by synthetic dsRNA, poly(I:C) as shown in the other three
panels. b In a single litter, a single prenatal poly(I:C) injection may cause different layering defects across pups including protrusions, intrusions
and laminar disorganization and other types of focal cortical dysplasia as well as pups with typical cortex. The cortical and ASD-like behavioral
MIA-caused phenotypes are dependent on maternal IL-17a. c A 9 year old ASD postmortem case with ADNP gene mutation has focal macroscopic
frontal cortical surface malformation (white arrow) and interruption of underlying cortical layering as visualized by expression of multiple layer-
specific and cell type specific markers (see region marked by the two light blue arrows; see Fig. 1 in Stoner et al [34]). Different marker genes
represented by different colors. This focal region also has clusters of mis-migrated cells (not shown in this section). Inset shows the same cortex
location visualized by nissl staining to further reveal surface undulation and protrusion (see black arrow). A 2 year old ASD postmortem case
shown in d with surface intrusions visualized by nissl staining and in e with surface intrusion visualized by multiple layer-specific and cell type
specific markers [34]. Adapted from Choi et al. [132] and Stoner et al. [34]
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to many other neuroanatomical and molecular abnormalities
found in ASD (Table 2).
Given the diverse ASD-associated phenotypes that arise
with a prenatal immune challenge, MIA-induced effects on
neurodevelopment provide insights into the molecular
mechanisms behind ASD and related neurodevelopmental
disorders. Within the ASD neuropathological and molecular
heterogeneous landscape, MIA disrupts fetal development
by involving transcriptional programs that are abnormal in
adult ASD brain tissue and genes with high-confidence
ASD mutations or their downstream targets [127]. This
evidence suggests shared disrupted pathways between
genetic and non-genetic etiologies and the possibility for a
much more relevant interplay between a genetic background
at-risk for ASD and environmental triggers. Work by Le
Belle et al. [130] identified that brain enlargement due to
Pten haploinsufficiency in mouse increased from 8 to 44%
when combined with MIA, thus demonstrating the inter-
active effects of MIA and ASD gene mutations in the dis-
ruption of cortical development. Such augmented disruption
occurs via the activation of the cellular redox signaling in
response to infection [130,133]. Reactive oxygen species
(ROS) can increase stem cell self-renewal and neurogenesis
through the reversible inactivation of PTEN and hyper-
activation of the NADPH oxidase (NOX)-PI3K pathway
[134], which ultimately, during early post-natal develop-
ment, will result in enlarged brains and autistic behaviors.
MIA also causes long-lasting deleterious effects on the
post-natal brain similar to those expected from germline
mutations in patients with neurodevelopmental disorders
[127]. Such effects likely involve the epigenetic dysregu-
lation of transcriptional programs that are sensitive to
environmental changes or insults [135–137]. Inflammatory
mediators (e.g., cytokines) induce such alterations during
neurodevelopment [138] by histone modifications [139],
methylation changes at the promoter of ASD-critical genes
(e.g., MECP2) [140] or genes involved in synaptic func-
tions [141] and global methylation changes [136]. Impor-
tantly, increased levels of IL-6 alone recapitulate aspects of
ASD pathophysiology [138, 142, 143]. At the molecular
level, IL-6 increases the activity of DNA methyltransferases
1 (DNMT1) with activating effects on the JAK/STAT3, NF-
κB and PI3K/AKT/mTOR signaling pathways [144–148]
affecting the regulation of autophagy-related functions, that
are required to maintain cellular homeostasis under stress
[149], such as a prenatal insult. This provides a strong link
between pro-inflammatory immune factors, body growth
through activation of the mTOR pathway and uncontrolled
proliferation typical of cancer-related disease [150, 151–153].
Genetic or epigenetic dysregulation of such pathways is
associated with several neurodevelopmental disorders, in
particular psychiatric, characterized by abnormal brain size
(enlarged and reduced) [154, 155]. Consistently, we found
that MIA alters key components of the TSC/mTOR sig-
naling pathway with ultimate activation of the translation
initiation factor EIF4E which is predicted to alter the reg-
ulation of neural progenitor cell divisions during mid-
gestation [127, 156–158]. Such regulation may also be
altered by activation of microglia cells under stress condi-
tions including MIA and/or in response to increase levels of
IL-6 [142]. Impairment in the regulation of microglia
functions is consistently seen in ASD studies [42, 159, 160]
and is likely involved in abnormal regulation of neuron
numbers both at pre- and post-natal stages.
Accumulating evidence consolidates the idea that envir-
onmental models of ASD-associated phenotypes may pro-
vide valuable insights to help develop potential treatment,
prevention, or intervention strategies. For example, MIA
alters expression in pathways shared with those in fragile X
syndrome for which advances in drug development are in
progress. With a better understanding of mechanisms
behind environmental etiologies of ASD, such as MIA, we
could potentially identify therapeutic targets amenable to
prevention and/or treatment later in life [161, 162]. In this
scenario, drugs that successfully target those pathways in
fragile X syndrome could potentially be re-purposed [127].
Other studies have used mesenchymal stem cells [163] or
Table 2 ASD-like molecular, cellular, anatomical and behavioral
abnormalities in MIA models
Human
development
Abnormalities induced by MIA and associated
with ASD
1st–2nd Trimester Upregulated cell cycle and downregulated
migration and neurite outgrowth gene
expression
Cortical layering: over-production of neurons,
increased cortical thickness, focal cortical
dysplasia
Cerebellar vermis dysplasia
2nd–3rd Trimester Microglia: enhanced priming, activation
Dendritic morphology abnormalities
GABAergic signaling, excitatory/inhibitory
imbalance, number of interneurons
3rd Trimester—
post-natal
White matter neuron density
Dendritic spines number and turnover rates
Synaptic pruning and proteins
Post-natal Early brain overgrowth
Myelin functionality and stability
Dopamine system
Serotonin levels
ASD-like abnormal social, vocalization, and
ritualistic behaviors
Gender-dependent effects
Transgenerational effects
See Supplementary Table S4 for references to individual studies
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pharmacological treatment to block or antagonize the effect
of MIA on purinergic [164] or inflammatory pathways [142,
165, 166].
Future directions: ASD Living Biology
Evidence shows that ASD begins during prenatal life, which
is the least studied and understood of all developmental
periods of ASD. This glaring gap poses a major barrier to
progress in ASD research and treatment and exists because
nearly all current approaches—postmortem, molecular,
genomic, genetic, computational and animal models—can-
not get answers to foundational questions such as: What are
the underlying molecular and cellular processes during fetal
and early post-natal stages that cause ASD in each child,
and how does this vary across children? How do different
prenatal trajectories explain and predict heterogeneity in
post-natal brain growth and functioning, behavior and
clinical profiles in ASD toddlers? Are there subtypes that
display normal fetal-stage development but begin abnormal
development at post-natal stages?
Nor can current approaches effectively examine more
targeted questions such as: How do different hcASD genes
affect fetal processes, and how are those effects related to
post-natal cognitive, language and social development? Is
there a difference in the brain development trajectory
between idiopathic ASD cases and ASD with mutations in
hcASD risk genes? Since macrocephaly is more strongly
related to ASD than to intellectual disability (ID) [62] and
many hcASD genes such as CHD8 and WDFY3 cause
dysregulation of proliferation and brain overgrowth
[193, 177, 183], what other fetal mechanisms are altered by
excess proliferation that lead to an ASD outcome? What are
the fetal-stage processes that alter imbalance between
excitation and inhibition that is proposed to explain learn-
ing, memory, sensorimotor, and cognitive deficits in ASD
[167]?
Post-natal phenotype data alone cannot reveal fetal-stage
biology, and fetal-stage cellular models alone cannot
explain post-natal development and clinical heterogeneity.
There is a need to bridge the gap between fetal and post-
natal biology for living ASD toddlers, and this requires a
paradigm shift. This paradigm we describe here, ASD
Living Biology, approaches the fundamental questions
above, by acquiring fetal and early post-natal measures
using iPS cells derived from skin or blood at any age, and
integrating them using a within-subjects design. Discovery
of the subtypes of prenatal pathogenic processes and their
interplay with post-natal experiences should be a major
direction for ASD research.
The ASD Living Biology approach will enable the
construction of quantitative multiscale models that could
address the perturbations in fetal-to-post-natal development.
These explanatory and predictive models of ASD could
address the disorder at the individual, subtype and group
level, when compared to models from typically developing
children. ASD Living Biology models would link in vitro
and in vivo data. In vitro data would include molecular,
cellular and physiological measures of a child’s iPS cells,
including measures of fetal-stage proliferation/differentia-
tion, cell fate and growth, synaptogenesis, synaptic function
and synchronized neural network activity. This iPSC based
approach could then be connected with in vivo measure-
ments from the same child, including their neural structural
and functional, genetic and genomic, behavioral, psycho-
metric, diagnostic and clinical outcome data. By thus inte-
grating such within-child fetal and post-natal measures, and
integrating these data, it will be possible to better under-
stand prenatal molecular mechanisms leading to the devel-
opment of ASD.
Interactions of post-natal biology and experiences
with preceding prenatal biology
Future research could also determine whether some ASD
prenatal trajectories are more deterministic of outcome
phenotype, while others might be easily modified by
experience, learning and interventions. The pleiotropic
effect of many hcASD genes raises the testable hypothesis
of a layered prenatal to post-natal path toward ASD in
which the disorder may be dynamically impacted by post-
natal changing functional roles of some ASD genes. It is
also possible that heterogeneity in ASD outcomes may
derive from the interplay of diverse prenatal dysregulations
with post-natal exposures. Post-natal changes are thought to
be reflected in changing behavioral and neurodevelop-
mental features [168] and some underlying mechanisms
have been proposed [169]. Perhaps different prenatal
pathogenic subtypes act as different general starting points
from which diverse post-natal experiences lead to further
variation in atypical development, some to higher and
others to lower risk for ASD. For each child, prenatal
starting points must be “worked around” to find optimal
adaptations for that individual. As a result, more or less
severe atypical behavior and cognitive outcomes may occur
[170, 171]. ASD Living Biology studies could be designed
to look at the interaction between atypical prenatal biology
and post-natal experience-based adaptation and how this
could lead to a spiral in early development that canalizes
[172] over time toward multiple, heterogeneous end points
(e.g., multifinality) [173]. Because neural circuits are
sculpted by experience, future designs could examine
whether atypical reduced social visual engagements from
very early in life in ASD [174–176], are the product of
some atypical prenatal to post-natal neural pathophysiology
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that causes an individual to engage in behavioral and cog-
nitive adaptations that result in decreased sampling of the
important social information necessary for typical social
brain development. The more atypical such post-natal
experience becomes, the more an individual’s develop-
ment could become canalized for atypical outcomes.
Conclusions
Multiple lines of postmortem, cellular, molecular, genomic,
genetic and animal model studies show that altered devel-
opment in ASD can begin as early as the 1st and 2nd tri-
mesters. Ninety-four percent of hcASD genes have peak
expression prenatally, with the vast majority affecting pro-
liferation/differentiation, cell fate, migration, neurite out-
growth and synaptogenesis. The majority are also
pleiotropic, affecting multiple developmental stages, not
just one. A commonly implicated pathway, RAS/ERK-
PI3K/AKT, is also pleiotropic and impacts multiple prenatal
stages from proliferation to synapse formation and function.
In different ASD individuals, variation in how and when
these pleiotropic pathways are dysregulated will lead to
different, even opposing effects, producing prenatal as well
as later neural and clinical heterogeneity. Thus, an excess or
reduction of synapse formation may occur in different ASD
cases; excess brain growth occurs in most while reduced
size occurs in a small subset. Nonetheless, in each indivi-
dual ASD child, multiple fetal-stage processes are dis-
rupted; one pathogenesis pattern is illustrated in Fig. 8 and
is based on Marchetto et al. [54]. Thus, the pathogenesis of
ASD is not set at one point in time and does not reside in
one process, but rather is a cascade of pathogenic processes.
This cascade can begin as early as the first trimester, with
alterations in cell proliferation and differentiation. The
process then continues throughout prenatal life and into the
early post-natal period of life. Affected regions include
frontal, temporal, parietal, occipital, cerebellar, striatal,
amygdala and hippocampal regions (Fig. 4). Remarkably,
one ASD child-based cellular model finds a 10-fold
decrease in spontaneous neural activity and a 6-fold
decrease in synchronized bursts of neural network activ-
ity, a type of defect theorized long ago [6]. This dysfunc-
tional network endpoint is not the “cause” of ASD but
rather appears to stand at the end of a long chain of prenatal
and early post-natal pathogenic changes (Fig. 8).
Fig. 8 ASD is a multistage, progressive disorder of prenatal brain development. ASD children show a continuum of disorder severity because a
wide range of heterogeneous insults can affect brain development in a not fully deterministic way. We propose the general theory that ASD arises
from disruption of gene regulatory circuits with multiscale, hierarchical consequences on brain development starting from very early fetal stages.
One possible prenatal trajectory of ASD is illustrated here. As compared with four fetal stages illustrated in typical development (lower panel;
increasing fetal age from left to right), this ASD trajectory begins in the 1st and 2nd trimesters with abnormally high rates of proliferation; this
results in excess neural precursor cells (ASD first panel). Disorder continues with disruption of migration, laminar disorganization, reduced cell
growth, and reduced neurite outgrowth, resulting in neurons with a 10-fold decrease in spontaneous neural activity (ASD second panel). At still
later stages, ASD neurons show defects in synaptogenesis, receptor and neurotransmitter development (ASD third panel). This deviant devel-
opment of neurons leads to abnormal neural circuitry with a 6-fold decrease in synchronized bursts of neural network activity (ASD fourth panel).
This also illustrates that ASD pathogenesis is not set at one point in time and does not reside in one process, but rather is a cascade of pathogenic
processes. Different causes and prenatal times of insult combined with individual-dependent background genetics may alter details of develop-
mental trajectories, resulting in differences in number, size and type of neurons in different cortical layers as well as number and functionality of
synapses. This fetal heterogeneity leads to post-natal heterogeneity in neural circuits, behavior and clinical outcomes. Discovery of prenatal causes,
processes and trajectories as they occur in children with ASD requires a paradigm shift: the ASD Living Biology approach. Courtesy of Eric
Courchesne and Vahid H. Gazestani
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ASD is a multi-etiology, multi-stage, progressive dis-
order that spans most of fetal life. In our theory, a single
perturbation can trigger a cascade of pathogenic changes,
such as an MIA event, a single fetal injection of XAV939
[112] or PTEN mutation in a child [54]. Multiple pertur-
bations may substantially amplify both the severity of dis-
order and outcome heterogeneity, such as, for example, a
combination of PTEN mutation and MIA [130]. Moreover,
many known and proposed ASD etiologies (e.g., MECP2,
PTEN, MIA, XAV939) may perturb the pleiotropic RAS/
ERK-PI3K/AKT pathway (Fig. 6), which in turn modulates
each of the ASD-critical fetal and early post-natal stages
discussed here. Dysregulated proliferation/differentiation
can be a potent perturbation because it can lead to abnormal
changes in subsequent stages of cell fate, migration, orga-
nization, maturation, and synapse and neural development
[54, 112]. Cell and animal models of high-confidence ASD
genes, such as CHD8, PTEN, WDFY3, definitively
show disruption of cell proliferation (Fig. 5; Table S2);
Fang et al. show robust synaptic, neural and behavioral
downstream effects of excess neuron proliferation [112],
and ASD patient-derived iPSC models show that excess
proliferation is a robust early fetal stage defect in every
case examined [54, 55].
Culprit prenatal perturbations do not necessarily produce
identical neural and clinical outcomes even when the per-
turbations are themselves identical in siblings. The Choi and
colleagues [132, 81] MIA ASD mouse model study showed
that the same fetal MIA perturbation of littermates causes
patches of focal cortical dysplasia that have marked het-
erogeneity, analogous to heterogeneity found in cortex in
unrelated individual ASD cases postmortem [34] (Fig. 7).
The Wdfy3 mutation mouse model of ASD likewise dis-
plays heterogeneity of migration and focal patch defects
across individual animals, as well as disrupted proliferation/
differentiation and cortical overgrowth [177]. In Courch-
esne et al. [24], two ASD individuals had >100% the nor-
mal mean prefrontal neuron number, but one had small
neurons and a modestly enlarged brain weight while the
other had typical neuron size and one of the largest brain
weights ever recorded for ASD. In the Marchetto et al. [54]
study, even though neural progenitors from every ASD
toddler doubled cell numbers faster than every control, the
proliferation rates among ASD toddlers varied and that
variation correlated with variation in MRI volume.
Because ASD begins in prenatal and early post-natal life,
there is an ethical demand for early detection, intervention
and services. When it is not detected in an infant or toddler,
it is because it was missed [178]. Studies demonstrate that
ASD risk can be measured as young as 12 to 24 months
using parent report screening tools such as the CSBS IT-
Checklist and M-CHAT at well-baby check-ups with
follow-up confirmation at ASD specialty clinics [179, 180].
This screening procedure is fast, easy, inexpensive and
effective, and can be done in any pediatric office or clinic
[179]. Studies show that when pediatricians and ASD spe-
cialty clinics work together, risk detection and diagnostic
evaluation can occur as early as 12 to 20 months, and
interventions soon thereafter [179, 181].
Early interventions and services may improve an ASD
child’s developmental outcome and help parents at a crucial
time in human brain development. During the first post-
natal years, the human brain undergoes a profound period of
establishing and refining neural connections, and this is the
basis for the emergence of higher-order social, language and
cognitive networks and behavior. This important develop-
mental step of the construction of functional and adaptive
neural circuits is dependent on adaptive neural responses to
input from the environment. If an infant or toddler with
ASD is identified and behavioral treatment begun before
or while early brain connections are being actively estab-
lished, then brain function for that toddler stands the best
chance of being improved. This is superior to treatment that
begins late and after abnormal mature circuitry is already
established. It is for this very reason that the early identi-
fication and treatment of ASD is essential and ethically
demanded [181].
Lastly, to address the progressive prenatal beginnings
and likely prenatal to post-natal experience-dependent
interactions in ASD, new treatment designs are needed.
We advocate coordinated in vitro and in vivo within-subject
ASD Living Biology research designs to provide early-age
molecular, cellular, and neuronal functional developmental
explanations for individual differences as well as across
ASD commonalities. Advances in stem cell model
systems enable this [182]: Patient-derived brain organoids
allow investigation of fetal processes that are remarkably
similar to in vivo development. Within-child in vitro
and in vivo designs could reveal prenatal and early post-
natal bases of outcome clinical heterogeneity. Through this
ASD Living Biology approach, relationships between
prenatal development and post-natal experience, learning,
brain growth and function, clinical presentation and
progression, and treatment responsiveness may be defined
at the individual level, thus enabling the development of
precision medicine approaches with truly beneficial
interventions.
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